Oxford Asset Management LLP Invests $419,000 in Organon & Co. (NYSE:OGN)

Oxford Asset Management LLP purchased a new stake in Organon & Co. (NYSE:OGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 28,111 shares of the company's stock, valued at approximately $419,000.

Several other institutional investors have also recently added to or reduced their stakes in OGN. Barclays PLC grew its holdings in shares of Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company's stock worth $2,285,000 after acquiring an additional 84,136 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Organon & Co. in the 3rd quarter valued at about $185,000. Optimist Retirement Group LLC acquired a new position in shares of Organon & Co. in the 3rd quarter valued at about $1,974,000. Tidal Investments LLC lifted its stake in shares of Organon & Co. by 10.6% in the 3rd quarter. Tidal Investments LLC now owns 76,525 shares of the company's stock valued at $1,464,000 after purchasing an additional 7,330 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Organon & Co. by 3.9% during the 3rd quarter. Franklin Resources Inc. now owns 344,138 shares of the company's stock worth $6,229,000 after acquiring an additional 13,029 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on OGN shares. TD Cowen upgraded Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Barclays dropped their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, Morgan Stanley dropped their target price on shares of Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Organon & Co. presently has a consensus rating of "Hold" and a consensus price target of $19.75.

Organon & Co. Price Performance

OGN traded down $0.22 during midday trading on Wednesday, reaching $12.94. 5,421,945 shares of the company's stock were exchanged, compared to its average volume of 2,746,094. The firm has a market capitalization of $3.36 billion, a price-to-earnings ratio of 3.89, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a one year low of $10.45 and a one year high of $23.10. The business has a 50-day simple moving average of $13.76 and a two-hundred day simple moving average of $15.09.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. As a group, research analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 8.66%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.